Prospective, Single-blinded, Randomized Comparison of the Clinical and Angiographic Results With Intravascular Analysis of EverolimuS-Eluting Versus ZoTarolimus-Eluting steNTs for In-Stent Restenosis (ISR) Lesions: Volumetric Analysis With Intravascular Ultrasound (IVUS) : Phase IV Multicenter Trial (RESTENT-ISR Trial).

Trial Profile

Prospective, Single-blinded, Randomized Comparison of the Clinical and Angiographic Results With Intravascular Analysis of EverolimuS-Eluting Versus ZoTarolimus-Eluting steNTs for In-Stent Restenosis (ISR) Lesions: Volumetric Analysis With Intravascular Ultrasound (IVUS) : Phase IV Multicenter Trial (RESTENT-ISR Trial).

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Everolimus (Primary) ; Zotarolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms RESTENT-ISR
  • Most Recent Events

    • 17 Sep 2016 Primary endpoint (In-stent neointimal volume index) has not been met, according to the article published in the European Heart Jouranl.
    • 15 Sep 2016 Results published in the European Heart Journal
    • 07 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top